AU2017348434B2 - Peripheral modifications on pocket-redesigned vancomycin analogs synergistically improve antimicrobial potency and durability - Google Patents

Peripheral modifications on pocket-redesigned vancomycin analogs synergistically improve antimicrobial potency and durability Download PDF

Info

Publication number
AU2017348434B2
AU2017348434B2 AU2017348434A AU2017348434A AU2017348434B2 AU 2017348434 B2 AU2017348434 B2 AU 2017348434B2 AU 2017348434 A AU2017348434 A AU 2017348434A AU 2017348434 A AU2017348434 A AU 2017348434A AU 2017348434 B2 AU2017348434 B2 AU 2017348434B2
Authority
AU
Australia
Prior art keywords
vancomycin
compound
ala
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017348434A
Other languages
English (en)
Other versions
AU2017348434A1 (en
Inventor
Dale L. Boger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of AU2017348434A1 publication Critical patent/AU2017348434A1/en
Application granted granted Critical
Publication of AU2017348434B2 publication Critical patent/AU2017348434B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K9/00Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2017348434A 2016-10-31 2017-10-31 Peripheral modifications on pocket-redesigned vancomycin analogs synergistically improve antimicrobial potency and durability Ceased AU2017348434B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662415191P 2016-10-31 2016-10-31
US62/415,191 2016-10-31
PCT/US2017/059289 WO2018081797A1 (en) 2016-10-31 2017-10-31 Peripheral modifications on pocket-redesigned vancomycin analogs synergistically improve antimicrobial potency and durability

Publications (2)

Publication Number Publication Date
AU2017348434A1 AU2017348434A1 (en) 2019-05-16
AU2017348434B2 true AU2017348434B2 (en) 2021-10-07

Family

ID=62024092

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017348434A Ceased AU2017348434B2 (en) 2016-10-31 2017-10-31 Peripheral modifications on pocket-redesigned vancomycin analogs synergistically improve antimicrobial potency and durability

Country Status (6)

Country Link
US (1) US10934326B2 (https=)
EP (1) EP3532483A4 (https=)
JP (1) JP7104424B2 (https=)
AU (1) AU2017348434B2 (https=)
CA (1) CA3042039C (https=)
WO (1) WO2018081797A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL270685B (en) 2017-05-22 2022-09-01 Insmed Inc Cleavable derivatives of lipoglycopeptide and their uses
EP4139328A4 (en) * 2020-04-20 2024-05-22 The Scripps Research Institute GUANIDINE-MODIFIED C-TERMINAL VANCOMYCIN COMPOUNDS, COMPOSITIONS AND METHODS
CN117069794B (zh) * 2023-06-20 2024-02-13 广州中医药大学(广州中医药研究院) 一种糖肽类抗生素荧光探针化合物及其制备方法与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998000153A1 (en) * 1996-06-28 1998-01-08 Eli Lilly And Company Amides

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2497159A1 (en) 2002-08-30 2004-03-11 K.U. Leuven Research And Development Glycopeptide antibiotic and semisynthetic derivatives thereof and their use as antiviral agents
US8778874B2 (en) 2004-11-29 2014-07-15 National University Corporation Nagoya University Glycopeptide antibiotic monomer derivatives
WO2012129493A1 (en) * 2011-03-24 2012-09-27 Seachaid Pharmaceuticals, Inc. Vancomycin derivatives
US10081655B2 (en) * 2011-11-14 2018-09-25 Jawaharlal Nehru Centre For Advanced Cationic antibacterial composition
CA2954653C (en) * 2014-07-10 2023-01-24 The Scripps Research Institute N-(hydrophobe-substituted)vancosaminyl [.psi.[c(=nh)nh]tpg4]vancomycin and [.psi.[ch2nh]tpg4]vancomycin
WO2018010475A1 (zh) * 2016-07-15 2018-01-18 上海来益生物药物研究开发中心有限责任公司 糖肽类衍生物及其药学可接受的盐、制备方法和应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998000153A1 (en) * 1996-06-28 1998-01-08 Eli Lilly And Company Amides

Also Published As

Publication number Publication date
JP7104424B2 (ja) 2022-07-21
AU2017348434A1 (en) 2019-05-16
EP3532483A4 (en) 2020-09-02
WO2018081797A1 (en) 2018-05-03
EP3532483A1 (en) 2019-09-04
CA3042039C (en) 2023-09-26
US20200071359A1 (en) 2020-03-05
US10934326B2 (en) 2021-03-02
JP2019534289A (ja) 2019-11-28
CA3042039A1 (en) 2018-05-03

Similar Documents

Publication Publication Date Title
EP3428170A1 (en) Anti-influenza polycyclic pyridone derivative and prodrug thereof
US11649222B2 (en) Compounds
AU2017348434B2 (en) Peripheral modifications on pocket-redesigned vancomycin analogs synergistically improve antimicrobial potency and durability
US10077284B2 (en) UBA5 inhibitors
AU2014259608A1 (en) Antimicrobial potentiators
EP2739289B1 (en) Glycopeptide antibiotic analogs effective against vancomycin-resistant bacterial strains
Pitcher et al. Development of 1, 2, 4-oxadiazole antimicrobial agents to treat enteric pathogens within the gastrointestinal tract
CA2954653C (en) N-(hydrophobe-substituted)vancosaminyl [.psi.[c(=nh)nh]tpg4]vancomycin and [.psi.[ch2nh]tpg4]vancomycin
Tengler et al. Synthesis and Biological Evaluation of 2‐Hydroxy‐3‐[(2‐aryloxyethyl) amino] propyl 4‐[(Alkoxycarbonyl) amino] benzoates
TW201711990A (zh) 經取代的丙二醯胺化合物及其作爲抗菌藥物的用途
Shi et al. Design, synthesis, and antibacterial activity of 2, 5-dihydropyrrole formyl hydroxyamino derivatives as novel peptide deformylase inhibitors
JP2016510749A (ja) キナゾリノン抗生物質
Sampson et al. Spiro-naphthyridinone piperidines as inhibitors of S. aureus and E. coli enoyl-ACP reductase (FabI)
US9951039B2 (en) Pyrimidines for treatment of bacterial infections
JP5756096B2 (ja) グアニンリボスイッチ結合化合物及び抗生物質としてのその使用
EP3209667B1 (en) Nargenicin compounds and uses thereof as antibacterial agents
CN110981888A (zh) N-芳基二硫吡咯酮脲类和氨基酯类衍生物及其制备和应用
Payne Synthesis of FtsZ Inhibitors: Potential Antibiotic Agents
WO2013154793A1 (en) F2 derivatives as antibacterial agents
Tengler et al. Research Article Synthesis and Biological Evaluation of 2-Hydroxy-3-[(2-aryloxyethyl) amino] propyl 4-[(Alkoxycarbonyl) amino] benzoates
Abel-santos The Design, Synthesis, and Inhibition of Clostridioides difficile Spore Germination by Acyclic and Bicyclic Tertiary Amide Analogs of Cholate

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired